RIP
IRD

Reliant Investment Partners’s Opus Genetics IRD Stock Holding History

Reliant Investment Partners’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.5K Hold
10,000
– – 0.04% 112
2025
Q4 		$20.1K Hold
10,000
– – 0.02% 109
2025
Q3 		$18.8K Hold
10,000
– – 0.01% 107
2025
Q2 		$9.42K Hold
10,000
– – 0.01% 110
2025
Q1 		$9.82K Hold
10,000
– – 0.01% 95
2024
Q4 		$11.9K Buy
+10,000
New +$11.5K 0.01% 110

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Reliant Investment Partners's IRD Position: Q1 2026 in Review

Reliant Investment Partners held its Opus Genetics (IRD) position steady in Q1 2026 at 10,000 shares worth $45.5K. The position accounts for 0.04% of the portfolio, ranked #112.

Reliant Investment Partners first reported a position in IRD in Q4 2024 and has held it in 6 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Reliant Investment Partners held 10,000 shares of Opus Genetics worth $45.5K as of Q1 2026.
  • Reliant Investment Partners left its Opus Genetics share count unchanged in Q1 2026.
  • Opus Genetics made up 0.04% of Reliant Investment Partners's portfolio in Q1 2026, its #112 holding.
  • Reliant Investment Partners first reported a position in Opus Genetics in Q4 2024 and has held it in 6 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Reliant Investment Partners's 13F filing for Q1 2026, filed 11 May 2026.